Scotia Foscan
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Agent receives "not approvable" designation Sept. 25. FDA is questioning the adequacy of the photo-sensitizing agent's 16% response rate in the palliative treatment of recurrent, refractory or secondary squamous cell carcinomas of the head and neck, the firm say